Boehringer Ingelheim expands its Business with Biosimilars

Ingelheim, September 26, 2011 - As part of its corporate strategy Boehringer Ingelheim announced today to establish a new separate business for the development and commercialization of own biosimilars.

Boehringer Ingelheim started more than 30 years ago as a pioneer in biopharmaceuticals with the development and manufacturing of biopharmaceutical therapeutics. Today Boehringer Ingelheim Biopharmaceuticals is one of the leading companies in this field straight following its strategy to serve best in class development and manufacturing for its clients and Boehringer Ingelheim itself.

"We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines", commented Prof. Dr. Wolfram Carius, member of the Board of Managing Directors and responsible for Operations. "We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality Biosimilars understanding patients' needs."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit